{"id":347189,"date":"2022-06-07T17:15:39","date_gmt":"2022-06-07T15:15:39","guid":{"rendered":"https:\/\/www.pcnen.com\/portal\/?p=347189"},"modified":"2022-06-07T17:15:39","modified_gmt":"2022-06-07T15:15:39","slug":"lijek-koji-budi-nadu-oboljelima-od-raka-rektum","status":"publish","type":"post","link":"https:\/\/www.pcnen.com\/portal\/2022\/06\/07\/lijek-koji-budi-nadu-oboljelima-od-raka-rektum\/","title":{"rendered":"Lijek koji budi nadu oboljelima od raka rektum"},"content":{"rendered":"<p>Lijek se zove dostarlimab i prodaje se pod robnom markom Jemperli. Radi se o imunoterapijskom lijeku koji se koristi u lije\u010denju raka vrata maternice, ali ovo je bilo prvo klini\u010dko istra\u017eivanje o tome je li efikasan i protiv raka debelog crijeva.<\/p>\n<p>Pozitivni rezultati do sada su vi\u0111eni samo kod 12 pacijenata (ispitivanje je i dalje u toku), od kojih su svi imali tumore s genetskim mutacijama zvanim nedostatak popravka neuskla\u0111enosti (MMRd), koji su vi\u0111eni u podgrupi od pribli\u017eno pet do deset posto pacijenata s rakom debelog crijeva, prenosi <a href=\"https:\/\/zimo.dnevnik.hr\/clanak\/100-posto-pacijenata-izlijeceno-novom-revolucionarnom-terapijom-protiv-raka-vjerujem-da-se-ovo-dogodilo-prvi-put-u-povijesti-te-bolesti---727711.html\" target=\"_blank\" rel=\"noopener\">zimo.dnevnik.hr.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mala, ali obe\u0107avaju\u0107a studija sprovedena u SAD ulila je nadu osobama koje boluju od raka rektuma. Iako je istra\u017eivanje sprovedeno na malom broju pacijenata, svi su nakon lije\u010denja eksperimentalnim lijekom u\u0161li u remisiju.<\/p>\n","protected":false},"author":1,"featured_media":347190,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"categories":[14],"tags":[1812,1811,707,1810],"class_list":["post-347189","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-vijesti","tag-dostarlimab","tag-jemperli","tag-lijek","tag-tumor"],"_links":{"self":[{"href":"https:\/\/www.pcnen.com\/portal\/wp-json\/wp\/v2\/posts\/347189","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcnen.com\/portal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcnen.com\/portal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcnen.com\/portal\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcnen.com\/portal\/wp-json\/wp\/v2\/comments?post=347189"}],"version-history":[{"count":1,"href":"https:\/\/www.pcnen.com\/portal\/wp-json\/wp\/v2\/posts\/347189\/revisions"}],"predecessor-version":[{"id":347191,"href":"https:\/\/www.pcnen.com\/portal\/wp-json\/wp\/v2\/posts\/347189\/revisions\/347191"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcnen.com\/portal\/wp-json\/wp\/v2\/media\/347190"}],"wp:attachment":[{"href":"https:\/\/www.pcnen.com\/portal\/wp-json\/wp\/v2\/media?parent=347189"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcnen.com\/portal\/wp-json\/wp\/v2\/categories?post=347189"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcnen.com\/portal\/wp-json\/wp\/v2\/tags?post=347189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}